• ABOUT THE AUTHOR
  • Sustainability
  • CSR
  • CSR reporting

In Good Company: Singh on CSR

~ Connecting the dots between Business, Society & the Environment

Tag Archives: health care

Access to Medicine, Transparency & Ethical Governance: GlaxoSmithKline’s 2012 CSR Report

09 Wednesday Jul 2014

Posted by Aman Singh in CSR, CSR reporting, CSRwire, ESG

≈ Leave a comment

Tags

avandia, carbon, clinical trials, community development, compliance, CSR, CSR report, CSR reporting, CSRwire, Disclosure & Transparency, Environment, ESG, Ethics, ethics, glaxosmithkline, governance, health care, paxil, Social Impact, Supply chain management, Sustainability, sustainability, Sustainability Report, transparency, vaccines, work culture


When a company is manufacturing critical need medicines and popular consumer products, how does it address increasing access to innovative products while managing its energy use?

On the launch of the GlaxoSmithKline’s 2012 Corporate Responsibility Report – a comprehensive read at 75 pages – I caught up with Director for Global Corporate Responsibility Clare Griffin for some updates.

Looking Ahead: GSK Switches Focus

For the first time the report, while focusing on the company’s 2012 performance, also includes a set of 23 forward-looking commitments across GSK’s business. The first thing that caught my eye in the report was the framework used to connect the firm’s vision with its business mission, assets, purpose and bottom line [see below]. How did the team use this chart to define CR’s focus at GSK?

“Lots of companies say they don’t have separate CR strategies; that they are completely embedded, etc. But how can you demonstrate that integration? This chart, for us, is a good way of explaining how CR is interwoven into our business. We have our business assets, our people, our priorities, our values, which leads us to create innovative products and drive access where people need it the most,” she explained.

“That’s the vision we want to create. We believe that if responsibility is absolutely integral to how we do business, we will deliver sustainable business growth for shareholders and benefits for our other stakeholders,” she added.

It’s all interrelated.

glaxosmithkline csr report

“For example, in the world’s poorest countries, our Developing Countries and Market Access (DCMA) operating unit has a clear objective to increase access to medicines and vaccines, while expanding our market presence and ensuring our business is sustainable for the long-term. This model is increasing our volume sales while increasing access to essential medicines and vaccines.”

Transparency, Pricing & Carbon: Challenges Ahead

“We will see through the implementation of our commitments on transparency of clinical trials data, continue with our commitments on pricing, and look to further harness manufacturing technologies to improve our carbon footprint,” writes GSK CEO Andrew Witty in the report.

Lots of promises in that one statement, I asked. How will these be implemented?

“We have a pretty diverse product line. Although pharmaceuticals are the majority, we also produce vaccines and consumer healthcare products. To improve our carbon emissions, we first invested in mapping our carbon footprint. For example, we found out that Amoxicillin, a very popular antibiotic, is Horlicksthe third-largest contributor to our carbon emissions due to the manufacturing process,” she said. “Our green chemistry team in Singapore has found a different way to produce Amoxicillin through using an enzyme instead which will cut carbon emissions from this process by 36,000 tonnes and reduce waste by 2,400 tonnes as well.”

Similarly with Horlicks, a popular malted milk drink: “We are working to further enhance an Indian government program aimed at modernizing milk production, and looking at introducing alternative energy generation, for example low-carbon biomass energy generation using waste wood to replace coal. Essentially, we are focusing on where we believe we can have the biggest impact,” she added.

Creating Access: Sharing Data From Clinical Trials

As for the transparency piece, while GSK has shared the summary results of all of its clinical trials – whether positive or negative – on a website accessible to all since 2004, the firm has committed to going further and now making anonymized patient-level data available to researchers.

“We’re setting up an independent panel which will review each request to make sure it is appropriate and will be using the data for valid scientific reasons. We also want the researchers to share their results back with the scientific community. We hope this initiative will be of value in developing and catalyzing a wider approach in the industry,” she explained.

Ethical Standards: Reinstating a Culture of Responsibility

Our discussion would not have been complete without taking into account, GSK’s rough tidings last year with the U.S. government. With the firm having to pay $3 billion to the U.S. government to settle allegations of unethical misconduct – failure to include information, etc. – in its sales and marketing practices around drugs Paxil and Avandia, several questions arose about the company’s corporate governance, accountability and sales practices – how do you move forward, I asked.

The company has taken significant steps to move beyond that, responded Griffin. “We have implemented a new incentive compensation system (Patient First) for our professional sales representatives who work directly with healthcare professionals in the U.S. The new system eliminates individual sales targets for these representatives as a basis for bonuses, and instead bases compensation primarily on sales competency, customer evaluations and the overall performance of their business unit,” she said.

glaxosmithkline csr report

The company has also brought together different Codes of Practices across regions and business units to create one Global Code and introduced standards that reinforce clear distinction between scientific dialogue and promotional activities. “These new standards govern the way we engage in scientific activities, such as advisory boards, publications, scientific congresses and medical education,” she said.

Other steps: A Corporate Ethics and Compliance Program for all employees, strengthened training programs, setting up an anti-bribery and corruption initiative and setting in motion disciplinary actions when needed.

“The 23 forward-looking commitments cut across the four areas of GSK’s responsibility: Health for all, Our behavior, Our People and Our Planet. It was important that we picked a time frame that is close enough that the current cadre of employees will be the people delivering the commitments while giving us enough time to create sustained change,” Griffin emphasized, alluding to the firm’s 2015 and 2020 goals.

Goals & Commitments: Highlights from 2012

So what were some of the year’s highlights for GSK?

  • The potential to bring around 15 new medicines and vaccines to patients over the next three years
  • 3.5 million pounds invested in R&D
  • 5 million pounds invested in the Tres Cantos Open Lab Foundation in Spain to fund research on solutions for diseases in the developed world
  • A concentrated focus on creating access, including monitoring the influential Access to Medicine Index, that measures what pharmaceuticals are doing to bring more medicines to more people [GSK won the top spot for the third time in 2012 although Griffin was quick to point out that “the index is a measure of what we’re doing, not the reason why we’re doing it.”]
  • A number of commitments around transparency established in 2012 including participating in the All-Trials Initiative, marking the next level of details on releasing results of GSK’s clinical trials.

What’s next?

“In 2013 we will continue to focus on innovation, access, and operating with transparency across the business. Specifically we will work to see through the implementation of our commitments on transparency of clinical trials data, continue with our commitments on pricing, and look to further harness manufacturing technologies to improve our carbon footprint,” finished Griffin.

Originally written for and published on CSRwire’s Commentary section Talkback onApril 16, 2013.

Advertisement

Share this:

  • Tweet
  • Email
  • Print

Like this:

Like Loading...

Earthwards 2.0: Johnson & Johnson Seeks to Evolve Sustainable Product Innovation

09 Wednesday Jul 2014

Posted by Aman Singh in CSRwire, ESG

≈ Leave a comment

Tags

andrew winston, Brand Management, CSR, CSRwire, earthwards, environment, Environment, ESG, health care, healthcare, hunter lovins, Innovation, lifecycle analysis, marks and spencer, Sustainability, sustainability, sustainability strategy, unilever, waste


In recent posts, I explored the genesis of Johnson & Johnson’s proprietary Earthwards® process and how it has been used to help develop greener products to meet customer needs. For Johnson & Johnson, the process of instilling a sustainability mindset began with introspection and questioning: How does an organization with multiple product lines and a global workforce develop and define greener products? And the process began with a tool called GAIA, or Global Aquatic Ingredient Assessment.

In the beginning, GAIA was operating almost exclusively with R&D because it was a science-based tool with specific emphasis on measuring downstream ecosystem impacts.  Implementation of the Earthwards process accelerated broader adoption and has helped spur greener product innovation based on lifecycle thinking that is, in part, quantified by tools like GAIA. But Earthwards, despite its rigor and initial success, is still in its infancy.

In 2012, Senior Director for Worldwide Environment Health and Safety Al Iannuzzi enlisted a team of experts that volunteered to examine the Earthwards process and recommend areas for improvement. What’s next? I explore the future of the program through the eyes of two well-respected sustainability experts who recently weighed in as part of that expert team: Andrew Winston and L. Hunter Lovins.

_____________________________

By now, you’ve probably caught a glimpse of that new inspiring Honda Civic 2013 commercial, framing innovation as believing that ‘things can always be better.’  For Winston, making things better begins by asking questions. “As we pursue sustainability in the future, asking the right questions will be as important as the answers we get,” he said.

For the people at Johnson & Johnson, the concept of continuous improvement is a driving force. So it makes sense that their efforts to evolve the current Earthwards methodology into a better process  began with some Earthwardshonest introspection and engagement with a few external experts, including Winston and Lovins.

In a recent phone call with Winston, I asked him his impressions of the Earthwards process.

He believes that the Earthwards process is a solid program with appropriate categories and logical steps that “empowers product developers with information and helps them understand the choices. It’s a well-designed system, but does have its pros and cons.”

I asked him to elaborate.

“They have the right categories, seven in all, but the concern is that a product could be improving in three distinct areas, but these may not be the most important areas to focus on in order to address the products’ greatest material impacts.  There’s a fine line between simplicity and enabling efficient assessments.”

Of course there are trade-offs. But the biggest challenge internally is giving employees the time and information they need to become comfortable with the Earthwards process and appreciate the impacts of improvements across the lifecycle.

“It is a fair point,” said Iannuzzi. “Our Review Board, including three external experts, also helps to keep the process objective, making sure that the brands focus their improvements on meaningful areas. To make this even more robust, we will require each application to address the lifecycle screen hot spot areas identified in step two of the Earthwards process, the lifecycle screen.”

Sufficiently Ambitious or Room for Improvement?

There is broad agreement among the experts that Johnson & Johnson has a long history of – and
interest in – environmental protection and sustainability. “The company has cared about its impact on the environment and on people, and taken a position of responsibility,” Lovins noted.

While both Lovins and Winston said that the Earthwards  process is one of the most comprehensive sustainable product tools in the industry, and in Lovins’ view, “a strong and rigorous process.” She also feels there is opportunity for the company to become even more aggressive in making this a companywide initiative.

“They need to examine the inadequacies of the Earthwards process, align it with tougher science-based goals and then make a commitment to hold every product to those goals.”

Winston had similar sentiments, specifically around the 10 percent benchmark Johnson & Johnson has set for improvements against Earthwards’ sustainability criteria. “The problem with a goal like 10 percent is that it’s kind of an internal-looking, corporate improvement. These goals at the product level need to be shooting for more dramatic increases.”

Some of J&J’s leading products are doing more than the required 10 percent anyway, so why stop there?

According to Iannuzzi, Johnson & Johnson sees the potential to raise the bar, perhaps substantially on some dimensions, but also recognizes the need to balance meaningful improvements within the original intent of Earthwards.

“J&J is always up for a challenge, but we want to make sure we don’t raise the bar so high that it becomes detrimental to Earthwards’ intended purpose of widespread adoption,” said Iannuzzi. “If we make the bar so high that almost no product can get there, no one would pursue it.”

 New Blueprint Needed?

According to a recent study commissioned by Johnson & Johnson titled The Growing Importance of Sustainable Products in the Global Health Care Industry, 54 percent of health care organizations globally say green attributes are very important in their purchasing decisions of health care products medical wasteand supplies. And this trend appears to be gaining traction, as 40 percent of global hospitals expect their future request for proposals to include sustainability criteria for the products they purchase. Among the greatest concerns hospitals share are the amount of energy they use and the volume of waste they generate.

With data like these indicating that the strongest push for sustainability is coming from within the healthcare sector, how will this influence the evolution of the Earthwards process?

To get at the heart of this question, Winston suggests that Johnson & Johnson ask itself whether doing better than 95 percent of its competitors is good enough.

In fact, Winston said Johnson & Johnson should go further than others and has challenged the company to raise the requirements for Earthwards recognition. For example, the baseline could be higher than the current 10 percent improvement needed to achieve recognition in the different categories, especially in the energy efficiency category, in light of the general scientific consensus that greenhouse gas emissions need to be reduced by 85 percent by 2050.

Iannuzzi responded: “We plan to better understand the greenhouse gas emissions impacts of the improvements we make this year with the Earthwards process and consider ways to further encourage them in our products.”

Lovins suggests the company be more transparent with customers about where it is in the process of sustainable product development and where it is going. Iannuzzi’s team is already responding by sharing more content on www.earthwards.com including more information about the 36 products that have received recognition so far and other external-facing efforts like a six-part series with CSRwire.

Internal Certification Process, Not a Sustainability Strategy

Coleman Bigelow, Johnson & Johnson Global Sustainability Marketing Director, sees the Earthwards program as an internal product stewardship and green marketing process rather than a long-term sustainability strategy like that of Marks & Spencer’s Plan A or Unilever’s Sustainable Living Plan.

The Earthwards process ensures “every product we produce has undergone a lifecycle screening and is as sustainable as possible. For the first time, we have a process that offers something to the developers, the R&D folks, as well as the marketers and sales associates,” Bigelow explained.

Iannuzzi, a Johnson & Johnson veteran of 28 years who has spearheaded the Earthwards program internally from the start and is a popular sustainability champion among the team, doesn’t foresee the company taking an approach akin to GE’s Ecomagination with a separate structure, either.

“Our philosophy is to embed sustainability into every product, not create something special or separate,” Iannuzzi explained. That said, the company does plan to track how much of its revenue stems from Earthwards recognized products. So while it is not its own revenue generating business unit, per se, it certainly could prove to save the company money over the long haul as well as drive innovation internally.

When I asked Iannuzzi about Earthwards’ ten-year plan, he reflected.

“Ideally, I envision it as a way of showing customers how we are coming up with more innovative products using sustainability as the driver. This means moving Earthwards process away from being an add-on and moving it toward full integration.  External communication will also be key.”

“But right now, it’s not as well integrated as we would like,” Iannuzzi admits.

Regardless, Winston seems convinced that Johnson & Johnson’s efforts have been both aggressive and innovative as a whole. The next tricky move for the company, say the experts, is to be mindful of how quickly the Earthwards program grows in scope without losing sight of the program’s quality.

As the team at Johnson & Johnson prepares for Earthwards round two, the experts’ advice should help the healthcare company scale its journey from green to greener without losing sight of the ultimate goal: A sustainable planet for future generations.

For now, it’s back to the white boards.

About Andrew Winston and L. Hunter Lovins

A globally recognized expert in green business strategies, Winston is the author of Green Recovery and co-author of Green to Gold, the international best-selling guide to what works – and what doesn’t – when companies go green. Winston is also founder of Winston Eco-Strategies, a sustainability consultancy dedicated to helping companies use environmental strategy to grow, create enduring value, and build stronger relationships with their stakeholders. He writes extensively on green business strategy, including a weekly column for Harvard Business Online and guest byline articles on Huffington Post.

Lovins is an award-winning sustainability consultant, featured speaker at conferences across the globe and author of Natural Capitalism: Creating the Next Industrial Revolution. Lovins is also president and founder of Natural Capitalism Solutions (NCS), which creates innovative, practical tools and strategies to enable companies, communities and countries to become more sustainable. Lovins is also a professor of sustainable business management at Bard College and Denver University, and consults for large and small companies, and governmental clients.

Originally written for and published on CSRwire’s Commentary section Talkback on March 13, 2013.

Share this:

  • Tweet
  • Email
  • Print

Like this:

Like Loading...

Let's Talk!

Virtual
732-322-7797
amansinghdas@gmail.com

Connect with me on Twitter

My Tweets

Blogs I Follow

  • Nonprofit Chronicles
  • Learned On by Andrea Learned
  • Angry African on the Loose™
  • csr-reporting
  • The CSR Blog
  • In Good Company: Singh on CSR

My Cloud

Capitalism 2.0 CSR CSR reporting CSRwire ESG Guest Author HR Stakeholder Engagement Sustainability Uncategorized

Recently written…

  • Rationality is Ruining Us: Mayors, presidents and governors join major businesses in charting way forward on climate change
  • 2015: the year businesses recognize that climate change is real – and 4 other themes
  • Hardcore lessons of sustainability – ’10 Words or Less’
  • Brewing a Better Future [#BaBF] with Heineken: Examining the Many Flavors of Local Sourcing
  • From Conflict to Collaboration: Kimberly-Clark and Greenpeace Participate in LIVE Twitter Chat

What others are reading

aman singh aman singh das Brand Management Business corporate social responsibility CSR CSR reporting CSRwire ESG Leadership Stakeholder Engagement supply chain Sustainability sustainability Work culture

Categories

Most Read

  • None

Create a free website or blog at WordPress.com.

Nonprofit Chronicles

Journalism about foundations, nonprofits and their impact

Learned On by Andrea Learned

Angry African on the Loose™

I have opinions. I am from Africa. I live here now. I blog.

csr-reporting

Connecting the dots between Business, Society & the Environment

The CSR Blog

Connecting the dots between Business, Society & the Environment

In Good Company: Singh on CSR

Connecting the dots between Business, Society & the Environment

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy
  • Follow Following
    • In Good Company: Singh on CSR
    • Join 119 other followers
    • Already have a WordPress.com account? Log in now.
    • In Good Company: Singh on CSR
    • Customize
    • Follow Following
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
 

Loading Comments...
 

    %d bloggers like this: